The result is in consistent with previous research on single or dual targeted anti‐HER2 neoadjuvant therapy,18, 19, 26, 28 indicating a limited response rate in HR‐positive/HER2‐positive (triple‐positive) breast cancers. Here, ERBB2 is linked to breast carcinoma.